Polymorphisms of the 5-hydroxytryptamine 2A/2C receptor genes and 5-hydroxytryptamine transporter gene in Chinese

Hongbin Chen1, Ke Hu, Jianyong Zhu

  • 1Division of Respiratory Disease, Renmin Hospital of Wuhan University, 99 Zhangzhidong Road, Wuchang, Wuhan, 430060, China.

Abstract

Insights

Genetic variations in serotonin receptors and transporters are linked to obstructive sleep apnea-hypopnea syndrome (OSAHS). The 5-HTR 2A gene A1438G polymorphism and 5-HTT-VNTR allele 10 may increase OSAHS susceptibility in the Chinese Han population.

Area of Science:

  • Genetics
  • Sleep Medicine
  • Pharmacogenomics

Background:

  • Obstructive sleep apnea-hypopnea syndrome (OSAHS) has a known genetic predisposition.
  • Polymorphisms in serotonin receptor genes (5-HTR 2A/2C) and the serotonin transporter gene (5-HTT) are potential contributors to OSAHS pathogenesis.

Purpose of the Study:

  • To investigate the prevalence of specific gene polymorphisms in the Chinese Han population with OSAHS.
  • To explore the association between 5-HTR 2A/2C and 5-HTT gene polymorphisms and OSAHS susceptibility.

Main Methods:

  • Genotyping of 226 Chinese Han individuals (121 OSAHS patients, 105 controls) using PCR-RFLP.
  • Analysis of A1438G and T102C polymorphisms in 5-HTR 2A, G796C in 5-HTR 2C, and LPR/VNTR polymorphisms in 5-HTT.

Main Results:

  • Significantly higher AA genotype and A allele frequencies of 5-HTR 2A A1438G polymorphism in OSAHS patients compared to controls.
  • Increased frequencies of 10/10, 12/10 genotypes and the 10 allele for 5-HTT-VNTR in the OSAHS group.
  • No significant differences for 5-HTR 2A T102C, 5-HTR 2C G796C, and 5-HTT-LPR polymorphisms between groups.

Conclusions:

  • The A1438G polymorphism of the 5-HTR 2A gene may play a role in OSAHS pathogenesis in the Chinese Han population.
  • 5-HTT VNTR polymorphism, specifically allele 10, appears to be associated with increased susceptibility to OSAHS.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...